Effect of β-blockers on endothelial function during biological aging: A nanotechnological approach

Journal of Cardiovascular Pharmacology

Volumn 51, Issue 2, 2008, Pages 208-215

  Funovic, Philip ^a   Korda, Mykhaylo ^b   Kubant, Ruslan ^c   Barlag, Rebecca E ^b   Jacob, Robert F ^c   Mason, R Preston ^d   Malinski, Tadeusz ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b OHIO UNIVERSITY   (United States)

^c ELUCIDA RESEARCH LLC   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

blockers; Biological aging; Endothelial nitric oxide synthase; L arginine; Nanosensors; Nitric oxide; Peroxynitrite; Superoxide demutase

Indexed keywords

ARGININE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM IONOPHORE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; METOPROLOL; NITRIC OXIDE; SEPIAPTERIN; SUPEROXIDE DISMUTASE;

AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL FUNCTION; ENDOTHELIUM; ENDOTHELIUM CELL; ENZYME ACTIVATION; NANOSENSOR; NANOTECHNOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT; WISTAR KYOTO RAT;

ADRENERGIC BETA-ANTAGONISTS; AGING; ANIMALS; AORTA, THORACIC; ARGININE; ATENOLOL; CELL AGING; ENDOTHELIUM, VASCULAR; METOPROLOL; NANOTECHNOLOGY; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PEROXYNITROUS ACID; PTERINS; RATS; RATS, INBRED WKY; SUPEROXIDE DISMUTASE;

EID: 39749146476     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31816017f8     Document Type: Article

References (41)

1. OEMAR BS, Tschudi MR, Godoy N, et al. Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis. Circulation. 1998;97:2494-2498.
2. Harrison DG, Freiman PC, Armstrong ML, et al. Alterations of vascular reactivity in atherosclerosis. Circ Res. 1987;61:74-80.
3. Liao JK. Endothelium and acute coronary syndromes. Clin Chem. 44;1799-1808.
4. Bonetti PO, Lerman LO, and Lerman A. Endothelial dysfunction: A marker of atherosclerotic risk. Arterioscler Thromb Vas Bio. 2003;23:168-175.
5. Vergnani L, Hatrik S, Ricci F, et al. Effect of native and oxidized low-density lipoprotein on endothelial nitric oxide and superoxide production: key role of L-arginine availability. Circulation. 2000;101:1261-1266.
6. Ignarro LJ, Buga GM, Wood KS, et al. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA. 1987;84:9265-9269.
7. Paniagua OA, Bryant MB, Panza JA. Role of endothelial nitric oxide in shear stress-induced vasodilation in human microvasculature. Diminished activity in hypertensive and hypercholesterolemic patients. Circulation. 2001;103:1752-1758.
8. Panza JA, Quyyumi AA, Brush JE, et al. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. New Engl J Med. 1990;323:22-27.
9. Taddei S, Virdis A, Mattei P, et al. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension. 1993;21:929-933.
10. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invet. 1997;100:2153-2157.
11. Brandes RP, Fleming I, Busse R. Endothelial aging. Cardiovasc Res. 2005;66:286-294.
12. Van der Loo B, Labugger R, Skepper JN, et al. Enhanced peroxynitrite formation is associated with vascular aging. J Exp Med. 2000;192:1731-1744.
13. Tschudi MR, Barton M, Bersinger NA, et al. Effect of age on kinetics of nitric oxide release in rat aorta and pulmonary artery. J Clin Invest. 1996;98:899-905.
14. Dobrucki IT. Restitution of nitric oxide synthesis and nitric oxide bioavailability in aging vasculature. PhD Dissertation, Ohio University, 2004.
15. Ladage D, Brixius K, Hoyer H, et al. Mechanism underlying nebivolol-induced endothelial nitric oxide synthase activator in human umbilical vein endothelial cells. Clin Exp Pharmacol Physiol. 2006;33:720-724.
16. Broeders MA, Doevendans PA, Bekkers BC, et al. Nebivolol: a third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta(2)-adrenergic receptor-mediated nitric oxide production. Circulation. 2000;102:677-684.
17. Kalinowski L, Dobrucki LW, Szczepanska-Konkel M, et al. Third-generation b-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation. 2003;107:2747-2752.
18. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). JAMA. 2000;283:1295-1302.
19. Drexler H, Hayoz D, Munzel T, et al. Endothelial function in chronic congestive heart failure. Am J Cardiol. 1992;69:1596-1601.
20. Drexler H, Hornig B. Endothelial dysfunction in human disease. J Mol Cell Cardiol. 1999;31:51-60.
21. Malinski T, Taha Z. Nitric oxide release from a single cell measured in situ by a porphyrinic-based microsensor. Nature. 1992;358:676-678.
22. Mesaro T, Vakova A, Grunfeld S, et al. Preparation and optimization of superoxide microbiosensor. Anal Chim Acta. 1998;358:27-33.
23. Wallenstein S, Zucker CL, Fleiss JL. Some statistical methods useful in circulation research. Circ Res. 1980;47:1-9.
24. Schlaich MP, Parnell MM, Ahlers BA, et al. Impaired L-arginine transport and endothelial function in hypertensive and genetically predisposed normotensive subjects. Circulation. 2004;110:3680-3686.
25. Kaye DM, Ahlers BA, Autelitano DJ, et al. In vivo and in vitro evidence for impaired arginine transport in human heart failure. Circulation. 2000;102:2707-2712.
26. Reddy DS, Singh M, Chopra K. Comparative antioxidant effects of beta-adrenoceptor blockers, calcium antagonists and U-74500A against iron-dependent lipid peroxidation in murine ventricular microsomal membranes. Meth Find Exp Clin Pharmacol. 1996;18:559-567.
27. Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol. 2005;25:29-38.
28. Clancy RM, Leszczynska-Piziak J, Abramson SB. Nitric oxide, an endothelial cell relaxation factor, inhibits neutrophil superoxide anion production via a direct action on the NADPH oxidase. J Clin Invest. 1992;90:1116-1121.
29. Janero DR, Lopez R, Pittman J, et al. Propranolol as xanthine oxidase inhibitor: implications for antioxidant activity. Life Sci. 1989;44:1579-1588.
30. Prabhu SD, Chandrasekar B, Murray DR, et al. Beta-adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. Circulation. 2000;101:2103-2109.
31. Hotamisligil GS, Peraldi P, Budavari A, et al. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science. 1996;271:665-668.
32. Tangeman HJ, Patterson JH. Extended-release metoprolol succinate in chronic heart failure. Ann Pharmacother. 2003;37:701-710.
33. Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest. 1996;97:1916-1923.
34. Berkenboom G, Langer I, Carpentier Y, et al. Ramipril prevents endothelial dysfunction induced by oxidized low-density lipoproteins: a bradykinin-dependent mechanism. Hypertension. 1997;30:371-376.
35. Morawietz H, Rohrbach S, Darmer D, et al. Angiotensin converting enzyme inhibitor treatment upregulates the expression of endothelial nitric oxide in human atrial myocardium. Circulation. 1996;94:3047.
36. Thai H, Wollmuth J, Goldman S, et al. Angiotensin subtype 1 receptor (AT1) blockade improves vasorelaxation in heart failure by up-regulation of endothelial nitric-oxide synthase via activation of the AT2 receptor. J Pharmacol Exp Ther. 2003;307:1171-1178.
37. Kalinowski L, Matys T, Chabielska E, et al. Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release. Hypertension. 2002;40:521-527.
38. Anderson TJ, Meredith IT, Yeung AC, et al. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. New Engl J Med. 1995;332:488-493.
39. Laufs U, La Fata V, Plutzky J, et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998;97:1129-1135.
40. Zhang X, Hintze TH. Amlodipine releases nitric oxide from canine coronary microvessels: An unexpected mechanism of action of a calcium channel-blocking agent. Circulation. 1998;97:576-580.
41. Wiklund O, Hulthe J, Wikstrand J, et al. Effect of controlled release/ extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia. Stroke. 2002;33:572-577.